Salman Osman, MD
Hematology & Oncology · Bridgeport, WVNPI 1285830091
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $103,593 of the $118,093 with a category attached, or 87.7%. E.r. Squibb & Sons, L.L.C. accounts for 95.8% of it on its own, with 11 other manufacturers making up the rest. Among hematology & oncology clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $1341.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$113K
- Bristol Myers Squibb$4K
- Incyte Corporation$281
- AstraZeneca$269
- Johnson & Johnson$233
- Medtronic$122
- plus $115 from 6 others
Across 5 payments — averaging $4325.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$21K
- E.r. Squibb & Sons, L.L.C.$975
What the payments were for
- Consulting fees$8,3057%
- Speaking & faculty fees$103,59388%
- Travel & lodging$3,5813%
- Food & beverage$2,2732%
- Education$3410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 67 | $113,149 |
| Bristol Myers Squibb | 3 | $3,923 |
| Incyte Corporation | 3 | $281 |
| AstraZeneca | 4 | $269 |
| Johnson & Johnson(2 entities) | 3 | $233 |
| Medtronic | 1 | $122 |
| Pfizer | 2 | $30 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $16 |
| Tempus AI, Inc | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$118,093 in reported general payments places this provider in the 95th percentile of 72 hematology & oncology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 80 | $1,175,135 |
| XtandiEnzalutamide | 50 | $670,352 |
| RevlimidLenalidomide | 29 | $521,812 |
| TasignaNilotinib Hcl | 19 | $434,349 |
| Lenalidomide | 28 | $393,395 |
| TazverikTazemetostat Hydrobromide | 17 | $346,313 |
| JakafiRuxolitinib Phosphate | 20 | $323,593 |
| IbrancePalbociclib | 20 | $293,359 |
| VenclextaVenetoclax | 23 | $250,815 |
| Abiraterone Acetate | 67 | $226,275 |
| SprycelDasatinib | 13 | $211,533 |
| GleevecImatinib Mesylate | 14 | $145,358 |
| Imatinib Mesylate | 28 | $45,474 |
| EliquisApixaban | 27 | $18,873 |
| Prochlorperazine Maleate | 64 | $2,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $269 | $1,175,13580 claims |
| Astellas Pharma US IncXtandi | $16 | $670,35250 claims |
| Bristol Myers SquibbRevlimid | $3,923 | $521,81229 claims |
| Incyte CorporationJakafi | $281 | $323,59320 claims |
| PfizerIbrance, Eliquis | $30 | $312,23147 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $113,149 | $211,53313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 72 hematology & oncology providers in West Virginia.
Other hematology & oncology in Bridgeport
- Swati VishwanathanBridgeport$3K
- Damian SilberminsHuntington$277K
- Abraham KanateMorgantown$169K
- Ashkan EmadiMorgantown$88K
- Konstantinos SdrimasMorgantown$81K
- Arvinder BirHuntington$74K
- Bhavana BhatnagarWheeling$72K
- Ihtishaam QaziMorgantown$18K
- Matias ValsecchiHuntington$17K
- Sonikpreet AulakhMorgantown$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.